Suppr超能文献

舍曲林对抑郁症血液透析患者血清CRP浓度的影响。

Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression.

作者信息

Zahed Narges Sadat, Sharifi Marjan, Karimi Mahdi, Nikbakht Hajar

机构信息

Loghman Hakim Clinical Research Development Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

J Renal Inj Prev. 2016 Aug 26;6(1):65-69. doi: 10.15171/jrip.2017.12. eCollection 2017.

Abstract

Depression is the most prevalent psychological problem among hemodialysis (HD) patients. Inflammatory factors have been reported to play an important role in the pathogenesis of depression. The association between depression and inflammatory factors was established in chronic kidney disease (CKD) patients. Sertraline, a selective serotonin reuptake inhibitor (SSRI) antidepressant, decreases serum levels of inflammatory factors in patients with depression. This study was designed to assess the effect of sertraline on serum concentration of C-reactive protein (CRP), hemoglobin and albumin of depressed hemodialysis (HD) patients. During a clinical trail, 35 depressed HD patients, and CRP >5 were allocated to receive sertraline for 12 weeks. Patients' depression was assessed using Beck depression inventory second edition (BDI-II) biochemical parameters (hemoglobin, serum albumin, etc) and CRP levels were measured at baseline and at weeks 4, 8 and 12 of the study. BDI-II score was evaluated before and after 12 weeks treatment with sertraline. Sertraline significantly improved depression symptoms in HD patients. At the end of the study, BDI-II scores significantly changed from baseline (=0.001) and serum levels of CRP significantly decreased at week 12 of initiation of the study (=0.001). However, the concentration of hemoglobin and serum albumin concentration and weight was not changed significantly (=0.995 and =0.328, respectively). Sertraline significantly decreases CRP levels and can be a promising strategy to reduce the systemic inflammation and to treat depression in HD patients.

摘要

抑郁症是血液透析(HD)患者中最普遍的心理问题。据报道,炎症因子在抑郁症的发病机制中起重要作用。抑郁症与炎症因子之间的关联已在慢性肾脏病(CKD)患者中得到证实。舍曲林是一种选择性5-羟色胺再摄取抑制剂(SSRI)类抗抑郁药,可降低抑郁症患者的血清炎症因子水平。本研究旨在评估舍曲林对抑郁血液透析(HD)患者血清C反应蛋白(CRP)浓度、血红蛋白和白蛋白的影响。在一项临床试验中,35名抑郁HD患者且CRP>5被分配接受舍曲林治疗12周。使用贝克抑郁量表第二版(BDI-II)评估患者的抑郁情况,在研究基线以及第4、8和12周测量生化参数(血红蛋白、血清白蛋白等)和CRP水平。在舍曲林治疗12周前后评估BDI-II评分。舍曲林显著改善了HD患者的抑郁症状。在研究结束时,BDI-II评分与基线相比有显著变化(P=0.001),且在研究开始后第12周血清CRP水平显著降低(P=0.001)。然而,血红蛋白浓度、血清白蛋白浓度和体重没有显著变化(分别为P=0.995和P=0.328)。舍曲林可显著降低CRP水平,可能是减轻HD患者全身炎症和治疗抑郁症的一种有效策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1c3/5414522/5e34bf4ee988/jrip-6-65-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验